Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
Paused · Phase 1/Phase 2
Conditions studied: Myelodysplastic Syndrome (MDS), Myelofibrosis (MF)
In brief
This is a global, multicenter, open-label, repeat-dose, Phase 1/2 study consisting of a Dose Escalation Phase (Phase 1) and a Cohort Expansion Phase (Phase 2). In both phases, KB004 will be administered by IV infusion once weekly as part of a 21-day dosing cycle.
Key facts
- Study ID
- NCT01211691
- Run by
- Humanigen, Inc.
- People needed
- 120
- Starts
- 2010-09-01
- Expected to finish
- 2016-12-01
- Last updated by the study team
- 2015-11-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study site — Palo Alto, California, United States
- Study site — Sacramento, California, United States
- Study site — Miami, Florida, United States
- Study site — Tampa, Florida, United States
- Study site — Manhattan, New York, United States
- Study site — Cleveland, Ohio, United States
- Study site — Houston, Texas, United States
- Study site — Adelaide, South Australia, Australia
- Study site — Prahran, Victoria, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.